Increasing awareness and knowledge of Alpha-gal Syndrome in the United States
This grant aims to boost awareness, knowledge, surveillance, and patient care for Alpha-gal Syndrome in the US by supporting professional collaboration, public education, and tracking of the condition.
Funder: Centers for Disease Control - NCEZID
Due Dates: June 7, 2026 (Optional letter of intent) | June 19, 2026 (Full application, 11:59 p.m. ET)
Funding Amounts: $25,000–$1,000,000 per 12-month budget period; up to 5 years; estimated total program funding $10,000,000–$25,000,000.
Summary: Supports projects to improve awareness, surveillance, and care for Alpha-gal Syndrome (AGS) through professional networks, education, and enhanced public health surveillance in the U.S.
Description
This funding opportunity from the CDC’s National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) aims to increase awareness and knowledge of Alpha-gal Syndrome (AGS), an emerging tick-borne allergy to mammalian meat and byproducts. AGS is not nationally notifiable and is underdiagnosed due to limited surveillance and low provider awareness. The program seeks to improve AGS surveillance, patient care, and public understanding by supporting the formation of professional networks, developing educational materials, and conducting active or enhanced surveillance activities.
Applicants may propose activities under three main strategies:
- Share: Establish and convene a network of AGS professionals (required).
- Educate: Develop and disseminate AGS communications and educational resources for healthcare providers, high-risk groups, and the general public (optional).
- Track: Conduct active or enhanced surveillance for AGS, especially in high-burden or underserved populations (optional).
Applicants must align with CDC priorities, including evidence-based approaches, transparency, and adherence to all applicable federal laws and policies.
